GOZZINI, ANTONELLA
 Distribuzione geografica
Continente #
NA - Nord America 1.755
EU - Europa 1.032
AS - Asia 362
SA - Sud America 37
OC - Oceania 13
AF - Africa 10
Totale 3.209
Nazione #
US - Stati Uniti d'America 1.744
RU - Federazione Russa 356
PL - Polonia 282
IE - Irlanda 104
CN - Cina 101
HK - Hong Kong 99
SG - Singapore 94
IT - Italia 87
SE - Svezia 85
BR - Brasile 33
FR - Francia 29
JO - Giordania 21
FI - Finlandia 20
DE - Germania 19
GB - Regno Unito 17
IN - India 17
UA - Ucraina 14
AU - Australia 13
CH - Svizzera 13
VN - Vietnam 12
CA - Canada 9
ID - Indonesia 9
CI - Costa d'Avorio 6
TR - Turchia 4
BE - Belgio 2
ES - Italia 2
IL - Israele 2
MX - Messico 2
VE - Venezuela 2
ZA - Sudafrica 2
AR - Argentina 1
AZ - Azerbaigian 1
BD - Bangladesh 1
EC - Ecuador 1
KE - Kenya 1
NL - Olanda 1
RS - Serbia 1
SC - Seychelles 1
TH - Thailandia 1
Totale 3.209
Città #
Santa Clara 575
Warsaw 282
Fairfield 154
Chandler 114
Dublin 104
Woodbridge 88
Ashburn 86
Seattle 83
Hong Kong 81
Cambridge 76
Singapore 64
Houston 62
Beijing 50
Wilmington 39
Ann Arbor 35
Lawrence 29
Princeton 29
Altamura 28
Buffalo 24
Paris 24
Florence 20
Jacksonville 18
Shanghai 16
Boston 15
Medford 14
Melbourne 13
Bern 12
Kent 11
Mumbai 11
San Diego 11
Dong Ket 10
Boardman 9
Moscow 9
Rome 9
Dearborn 7
Norwalk 7
Abidjan 6
Jakarta 6
Turin 6
Los Angeles 5
Renton 5
The Dalles 5
Toronto 5
Notre Dame 4
Yubileyny 4
Detroit 3
Falls Church 3
Hillsboro 3
Malang 3
Munich 3
Phoenix 3
Pune 3
Tappahannock 3
Turku 3
Andover 2
Barcelona 2
Bremen 2
Brussels 2
Council Bluffs 2
Izmir 2
Karlskrona 2
Kochi 2
London 2
Milan 2
Montréal 2
New York 2
Nuremberg 2
Piancogno 2
Portsmouth 2
Rio de Janeiro 2
Rubano 2
Salerno 2
Smolensk 2
São Paulo 2
Tel Aviv 2
Trumbull 2
Ankara 1
Auburn Hills 1
Baku 1
Baotou 1
Barueri 1
Bauru 1
Belgrade 1
Belo Horizonte 1
Brooklyn 1
Cape Town 1
Capinzal 1
Caracas 1
Carandaí 1
Castel Volturno 1
Castelliri 1
Cerignola 1
Cleveland 1
Costa Mesa 1
Cotia 1
Croydon 1
Cuenca 1
Cuneo 1
Curitiba 1
Duque de Caxias 1
Totale 2.360
Nome #
Targeting chronic myeloid leukemia stem cells with the hypoxia-inducible factor inhibitor acriflavine. 296
Targeting the Extracellular Signal-Regulated Kinase 5 Pathway to Suppress Human Chronic Myeloid Leukemia Stem Cells 243
Severe hypoxia selects hematopoietic progenitors with stem cell potential from primary Myelodysplastic syndrome bone marrow cell cultures. 218
Redistribution of H3K27me3 and acetylated histone H4 upon exposure to azacitidine and decitabine results in de-repression of the AML1/ETO target gene IL3. 163
In Vitro Comparison of the Effects of Imatinib and Ponatinib on Chronic Myeloid Leukemia Progenitor/Stem Cell Features 156
Acetylome and phosphoproteome modifications in imatinib resistant chronic myeloid leukaemia cells treated with valproic acid. 149
Mutated ASXL1 and number of somatic mutations as possible indicators of progression to chronic myelomonocytic leukemia of myelodysplastic syndromes with single or multilineage dysplasia 148
Selective anti-leukaemic activity of low-dose histone deacetylase inhibitor ITF2357 on AML1/ETO-positive cells 145
Time- and residue-specific differences in histone acetylation induced by VPA and SAHA in AML1/ETO positive leukemia cells 143
Expression of nucleoside-metabolizing enzymes in myelodysplastic syndromes and modulation of response to azacitidine 143
Genetic predisposition and induced pro-inflammatory/pro-oxidative status may play a role in increased atherothrombotic events in nilotinib treated chronic myeloid leukemia patients. 133
Expression of nucleoside-metabolizing enzymes in myelodysplastic syndromes and modulation of response to azacitidine. 133
Long-term outcome of chronic myeloid leukemia patients treated frontline with imatinib 120
Salarin C inhibits maintenance of hypoxia-selected Chronic Myeloid Leukemia progenitor cells 113
Targeting chronic myeloid leukemia stem cells with ERK5 pathway inhibitors 109
Complete remission with brentuximab vedotin in a case of primary cutaneous gamma-delta T-cell lymphoma relapsed after allogeneic stem cell transplantation 106
SPECIFIC DEGRADATION OF THE AML1-ETO/COREPRESSOR COMPLEX BY A NOVEL ORAL HYDROXAMIC ACID DERIVATIVE 102
Butyrates as single drug induce histone acetylation and granulocytic maturation: possible selectivity on core binding factor-acute myeloid leukemia blasts. 101
MAPKS ARE INVOLVED IN THE SURVIVAL AND DIFFERENTIATION OF A T(8;21) ACUTE MYELOID LEUKEMIA CELL LINE AND ARE MODULATED BY THE HDAC INHIBITOR D1 98
INCUBATION OF MURINE ERYTHROLEUKEMIA CELLS IN SEVERE HYPOXIA INDUCES MASSIVE APOPTOSIS PARALLELED BY AKT AND ERK5 CLEAVAGE 94
HDAC INHIBITORS IN COMBINATION WITH HYPOMETHYLATING AGENTS INDUCE SPECIFIC CHROMATIN MODIFICATION AND TRANSCRIPTIONAL ACTIVATION IN CBF/AML CELLS 91
EPIGENETIC MODIFICATIONS IN A T(8;21) ACUTE MYELOID LEUKEMIA CELL LINE CAUSED BY ADMINISTRATION OF THE HDAC INHIBITOR D1 89
ACETYLATION INDUCED BY BUTYRATES IN PATIENTS WITH ACUTE MYELOID LEUKEMIA CAN LEAD TO DIFFENTIATION 83
Iron overload and iron chelation therapy in patients with myelodysplastic syndrome treated by allogeneic stem-cell transplantation: Report from the working conference on iron chelation of the Gruppo Italiano Trapianto di Midollo 82
Totale 3.258
Categoria #
all - tutte 9.130
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 9.130


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20209 0 0 0 0 0 0 0 0 0 0 0 9
2020/2021318 19 35 3 34 14 41 27 26 38 41 14 26
2021/2022171 9 12 14 9 2 6 3 12 2 13 34 55
2022/2023494 41 98 37 33 27 78 69 21 52 2 16 20
2023/2024201 10 17 24 8 15 19 9 58 3 4 19 15
2024/20251.324 44 132 99 193 424 244 3 51 36 47 33 18
Totale 3.258